Economic Evaluation and Cost-Effectiveness Thresholds
暂无分享,去创建一个
[1] Nuala Moran. Report blames NICE for hastening decline of UK biotech , 2009, Nature Biotechnology.
[2] K. Davis. Slowing the growth of health care costs--learning from international experience. , 2008, The New England journal of medicine.
[3] Elias Mossialos,et al. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. , 2005, The International journal of health planning and management.
[4] M. Weinstein,et al. Medicare and cost-effectiveness analysis. , 2005, The New England journal of medicine.
[5] David C. Mowery,et al. Innovation in global industries : U.S. firms competing in a new world : collected studies , 2008 .
[6] T. Philipson,et al. Cost-effectiveness analysis and innovation. , 2008, Journal of health economics.
[7] J. Vernon,et al. Economic and Developmental Considerations for Pharmacogenomic Technology , 2012, PharmacoEconomics.
[8] Mark Sculpher. NICE’s 2008 Methods Guide , 2012, PharmacoEconomics.
[9] F. Hayek. The economic nature of the firm: The use of knowledge in society , 1945 .
[10] S. Iliffe. Thriving on challenge: NICE’s dementia guidelines , 2007, Expert review of pharmacoeconomics & outcomes research.
[11] M. Drummond,et al. Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .
[12] S. Zenios,et al. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] David Parkin,et al. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.
[14] George W. Torrance,et al. Social preferences for health states: An empirical evaluation of three measurement techniques , 1976 .
[15] M. Giacomini. How good is good enough? Standards in policy decisions to cover new health technologies. , 2007, Healthcare policy = Politiques de sante.
[16] Kevin M. Murphy,et al. The Economic Value of Medical Research , 2000 .
[17] Hendrik van den Bussche,et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.
[18] D. Feeny,et al. Using Health-Related Quality of Life Assessments to Evaluate Care Support Within Medicaid , 2008, Care Management Journals.
[19] P. Neumann. Why don't Americans use cost-effectiveness analysis? , 2004, The American journal of managed care.
[20] Martin McKee,et al. Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union , 2008 .
[21] Michael E. Chernew,et al. Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[22] P. Danzon,et al. The economics of gene therapy and of pharmacogenetics. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[23] Kevin M. Murphy,et al. Measuring the Gains from Medical Research: An Economic Approach , 2003 .
[24] T. Philipson,et al. Cost-effectiveness as a price control. , 2007, Health affairs.
[25] J. Vernon,et al. Mathematical Modeling and Pharmaceutical Pricing: Analyses Used to Inform In-Licensing and Developmental Go/No-Go Decisions , 2005, Health care management science.
[26] T. Abbott,et al. The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisions , 2007 .
[27] Frank A. Sloan,et al. Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .
[28] A. Enthoven,et al. The history and principles of managed competition. , 1993, Health affairs.